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RESUMEN 
 
Introducción  A pesar de su degradación por ectonucleotidasas, la concentración intersticial del trifosfato de adenosina ([ATP]out) aumenta después de un 
infarto agudo del miocardio (IAM) y se correlaciona con la ocurrencia de latidos ventriculares prematuros y taquicardia ventricular. Recien-
temente se demostró que el ATP extracelular activa una corriente despolarizante arritmogénica transportada por canales TRP (“Transient 
Receptor Potential”) TRPC3/7. Una estrategia para prevenir las arritmias durante un episodio isquémico agudo puede ser reducir [ATP]out. 
Resultados previos de nuestros laboratorios, en un modelo de IMA en rata, sugieren que este puede ser el caso.  
Objetivos      Estudiar si la creatina extracelular puede servir de “buffer” para el incremento súbito de [ATP]out y reducir los eventos arrítmicos en un mode-
lo de IMA en corazón aislado de rata. 
Método      Se  registraron  las actividades  eléctrica y contráctil en corazones aislados de rata perfundidos con la técnica de Langendorff. La arteria 
coronaria izquierda se ligó para inducir un infarto del miocardio. 
Resultados   En condición control, la creatina (1-3 mmol/L) no tuvo efectos importantes sobre las duraciones del QRS y del QT, así como tampoco sobre 
el intervalo RR o la fuerza de contracción. La ligadura de la arteria coronaria izquierda redujo marcadamente el umbral de fibrilación ventricu-
lar (UFV). No obstante, cuando los corazones fueron tratados previamente con creatina (1-3 mmol/L), el UFV fue significativamente mayor 
después del IMA, cuando se comparó con los corazones no tratados. Más aún, en corazones perfundidos con creatina después de ligar la 
arteria coronaria, el UFV también se incrementó pero en menor magnitud.  
Conclusión    Nuestros resultados sugieren que la creatina, a una concentración relativamente alta, puede servir como “buffer” para la liberación súbita de 
ATP durante la fase inicial de la isquemia y tener, por tanto, un efecto antiarrítmico. 
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ABSTRACT 
 
Introduction  Despite its degradation by ectonucleotidases, interstitial adenosine triphosphate concentration ([ATP]out) increases after an acute myocardial 
infarction (AMI) and correlates with the occurrence of ventricular premature beats and ventricular tachycardia. It has been recently shown 
that extracellular ATP activates a depolarizing arrhythmogenic current carried by the transient receptor potential (TRP) channels TRPC3/7. A 
decrease in [ATP]out could be a strategy to prevent arrhythmias during an acute ischemic episode. Previous results from our laboratories in a 
rat model of AMI suggest that this could be the case. 
Objective    To study whether extracellular creatine would serve as a buffer for the sudden increase of [ATP]out and decrease arrhythmic events in an 
isolated rat heart model of AMI. 
Method        Electrical and contractile activities were recorded on isolated Langendorff perfused rat hearts. The left coronary artery was occluded to induce 
a myocardial infarction. 
Results        Under control condition, creatine (1-3 mmol/L) had no major effects on QRS and QT durations nor on RR interval or force of contraction. The 
ligature of the left coronary artery markedly decreased the ventricular fibrillation threshold (VFT). However, when hearts were previously 
treated with creatine (1-3 mmol/L) the VFT was significantly higher after the AMI compared to untreated hearts. Moreover, in hearts perfused 
with creatine after coronary ligature, VFT was also increased but to a lesser extent. 
Conclusion   Our results suggest that creatine, at a relatively high concentration, would serve as a buffer for the sudden release of ATP during the early 
phase of ischemia thus having an antiarrhythmic effect. 
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INTRODUCTION 
 
Besides its role in cellular energetics and me-
tabolism adenosine triphosphate (ATP), can mo-
dulate the activity of several tissues including the 
heart. 1 In normal conditions, due to continuous 
degradation by ecto-ATPases, extracellular ATP 
concentration is in the nanomolar range. How-
ever, under pathological situations such as myo-
cardial ischemia and infarction, more specifically 
during the initial phase of an acute myocardial 
infarction (AMI), the extracellular (interstitial) ATP 
concentration ([ATP]out) could rise locally to a 
micromolar level 2, 3 or even hundreds of micro-
moles during thrombus formation due to an im-
paired blood flow.4 The increase in [ATP]out (and 
also of uridine triphosphate, UTP) during the early 
phase of an AMI triggers a cationic (nonspecific) 
current that induces abnormal automatic activity 
and arrhythmias.5 Alvarez and co-workers 6, de-
monstra-ted that a sudden increase in extracellu-
lar ATP (such as it occurs during a myocardial 
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infarction or ischemia) activates a cationic non-
specific current that is transported through the 
heteromeric transient receptor potential 
TRPC3/C7 channel. The signaling cascade that 
leads to TRP channel activation includes: the 
activation of a P2Y2 purinergic receptor by free 
ATP (ATP-4), activation of a Gq protein with the 
subsequent activation of the β isoform of phos-
pholipase C (PLC) which in turn hydrolyzes the 
phosphatidyl inositol 4, 5-bisphosphate into diacyl 
glycerol (DAG) and inositol-1, 4, 5-triphosphate 
(IP3). DAG activates the protein kinase C (PKC) 
which phosphorylates and activates the 
TRPC3/C7 channel.6 TRP channels are expressed 
in almost all mammalian cells including human 
and are responsible of the under-lying mechan-
isms of important physiological functions and 
physiopathological conditions.7, 8 
From a physiological point of view elucidation 
of this basic mechanism of ATP-induced arrhyth-
mias is important but it is also relevant to thera-
peutics since one or more new pharmacological 
targets were defined. This could allow the deve-
lopment of compounds acting on these targets to 
prevent cardiac arrhythmias. In this sense, results 
from our laboratories indicated that in a rat model 
creatine could prevent arrhythmias during the 
early phase of an AMI.9 The rationale for this is as 
follows: The existence of ecto-nucleoside diphos-
phate kinases (NDPK) has long been docu-
mented.10 The NDPK transfers phosphate groups 
between ATP and creatine to form creatine phos-
phate or vice versa. Thus, an excess creatine 
could prevent the action of ATP-4, which will be 
degraded to ADP (inactive on the TRPC3/C7 
channel) to form creatine phosphate by the 
NDPK. Creatine is naturally synthesized in liver 
and kidneys from the amino acids L-arginine, 
glycine and L-methionine and is transported to 
and used in the energy metabolism in muscles.11 
Creatine is widely used as a natural dietetic sup-
plement and by high performance athletes.12 
The aim of the present work was to extend our 
studies to an isolated rat heart model and to de-
termine whether creatine could have an antiarr-
hythmic action during an AMI. 
 
METHODS 
 
Experiments were performed on male adult 
Wistar rats. Under penthobarbital anesthesia, 
hearts were carefully dissected and mounted in a 
Langendorff column. They were perfused at cons-
tant flow (10 mL/min) with a Tyrode solution of the 
following composition (mmol/L): NaCl 140; KCl 
2.5; MgCl2 0.5; CaCl2 2; Tris-hydroxymethylami-
nomethane 10; Glucose 5 (pH = 7.4, gassed with 
O2; T = 35°C). Creatine (Sigma, USA) was directly 
dissolved in Tyrode solution. A bipolar platinum 
recording electrode was placed on the right ven-
tricular epicardium and the surface electrocardio-
gram (ECG) was recorded with a biophysical am-
plifier (AVB-10; Nihon Kohden, Japan). Another 
bipolar platinum electrode was placed near the 
atrioventricular ring and was connected to an 
electronic stimulator (SEN-7103; Nihon Kohden, 
Japan) through a stimulus-isolating unit (SS-102J; 
Nihon Kohden, Japan). Cardiac apex was fixed to 
a force-displacement transducer (SB-1T; Nihon 
Kohden, Japan) with a surgical 5-0 silk thread. 
The force of contraction (FC) was recorded using 
a low-level DC preamplifier (ACH-8; Nihon Koh-
den, Japan). Analog signals (ECG and FC) were 
digitized (100 μs sampling interval) using an 
AD/DA converter (Labmaster TL-1-125, Mentor, 
Ohio, USA), stored on a PC and analyzed off-line 
with the ACQUIS1 software (CNRS License, 
France). ECG and FC values were recorded at the 
spontaneous heart rate. Hearts were let to stabil-
ize for at least 30 min before beginning the expe-
riments. The ventricular fibrillation threshold (VFT) 
was determined using a stimulation program that 
consisted of twenty 2-ms duration current pulses 
at 2-ms interval. Current intensity (mA) was 
measured with the stimulus-isolating unit. VFT 
was the current intensity at which at least 5 spon-
taneous arrhythmic complexes were observed 
after the end of the stimulus train. All recordings 
were made under control condition and after oc-
clusion of the left coronary artery at pro-ximal 
point below the left atrial appendage using a sur-
gical 0 silk thread. 
Three experimental series were performed. In 
the first one  (N = 6),  hearts  were perfused un-
der control conditions and after a 30 min stabiliza-
tion period, the physiological variables were rec-
orded. Thereafter, the left coronary artery was 
occluded and after 5 min all physiological va-
riables were again recorded. In the second expe-
rimental series (N = 6), hearts were initially per-
fused with control solution and after all physiolog-
ical variables were recorded, creatine (1 or 3 
mmol/L) was added to the Tyrode solution. Hearts 
were let to stabilize for 10 min and all physiologi-
cal variables were again recorded. After this, and 
always in the presence of creatine, the left coro-
nary artery was occluded and the physiological 
variables were recorded as in the first experimen-
tal series. The third experimental series (N = 5) 
was the same as the first one except that after left 
coronary artery occlusion, creatine (1 or 3 
mmol/L) was added to the perfusion solution.  
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QTQT =
RR
Tabla 1. Electrical and contractile activities of spontaneous isolated rat hearts in control condition and after an Acute Myocardial Infarction (AMI): Absence of effects of 
creatine (1 - 3 mmol/L) 
 
 RR (ms) QRS duration (ms) QTc (ms) Force of Contraction (mN) Contraction duration (ms) 
Control 285.0 ± 16.5 13.7 ± 2.5 11.9 ± 0.7 154.3 ± 12.6 223.8 ± 10.1 
AMI 312.6 ± 27.9 * 13.5 ± 2.3 12.1 ± 1.5 101.0 ± 20 * 242 ± 12.2 
Creatine before AMI 305.8 ± 28.8 12.0 ± 2.8 12.1 ± 1.5 149.9 ± 5.2 227.0 ± 17.6 
 
Creatine + AMI 
 
365.9 ± 39.9 * 15.8 ± 1.7 12.1 ± 0.8 82.7 ± 20.1 * 232.5 ± 19.7 
Creatine after AMI 368.7 ± 15.3 * 15.3 ± 3.9 9.5 ± 0.8 83.9 ± 14.0 * 260.2 ± 24.9 
 
Data for AMI (with or without creatine) represent values obtained after 5 minutes of coronary artery occlusion. * p < 0.05, with respect to control.  
 
 
Results were analyzed using a Student's t-test 
for paired or unpaired samples as required using 
the Gnumeric Spreadsheet (Gnome Project, ver-
sion 1.10.17). Differences were considered statis 
tically significant for p < 0.05. Results are ex-
pressed as Means ± Standard Errors of Means. 
 
RESULTS 
 
Table 1 summarizes values for RR interval, 
QRS duration, corrected QT duration (QTC =  
QT/√RR) and FC under control condition. In this 
condition the VFT was 42.0 ± 3.2 mA (N = 17).  
Since results obtained with creatine 1 or 3 mmol/L 
were not statistically different, they were pooled 
together and are presented as “creatine”. As can 
be seen in Table 1, under control condition crea-
tine had no statistically significant effects on the 
electrical and contractile activities or on the VFT. 
There was a tendency, however, to increase the 
RR interval, which was not statistically significant. 
Acute myocardial infarction (AMI) was achieved 
by occluding the left coronary artery (see Me-
thods). Successful occlusion was recognized by 
pallor of the anterior left ventricular wall and by 
the occurrence of immediate decrease in contrac-
tile force. Acute myocardial infarction (5 minutes), 
induced by left coronary artery occlusion (AMI), 
significantly (p < 0.05) increased RR interval and 
decreased the force of contraction FC by 28 ms 
and 35%, respectively (Table 1). At this time, the 
VFT was significantly decreased by 62.1 ± 12.6 % 
(p < 0.05; Figure 1). 
Creatine did not prevent the increase in RR in-
terval or the decrease in FC by myocardial infarc-
tion (Table 1). However, in creatine-treated hearts 
after an AMI the VFT was significantly higher than 
in control infarcted hearts (Figure 1). Moreover, 
although creatine treatment after AMI did not re-
cover RR or FC values (Table 1) it exhibited a 
tendency to increase the VFT (Figure 1). 
 
 
 
Figure 1: Creatine increased the ventricular fibrillation threshold (VFT) during 
an acute myocardial infarction (AMI) in isolated Langendorff perfused rat 
hearts. Ligature of left coronary artery markedly decreased the ventricular 
fibrillation threshold (VFT). However, when hearts were previously treated 
with creatine (1 - 3 mmol/L) VFT after the AMI was significantly higher than in 
untreated hearts. Moreover, in hearts perfused with creatine after coronary 
ligature, VFT was also increased but to a lesser extent. * p < 0.05 with 
respect to control; ** p <0.05 with respect to infarct. 
 
DISCUSSION 
 
The present study strengthens the idea that 
creatine could have an antiarrhythmic action in 
the early stages of an acute myocardial infarction, 
extending and confirming our previous results in a 
rat model of AMI 9. In that study we demonstrated 
that intraperitoneal injection of creatine significan-
tly decreased arrhythmias (ventricular premature 
beats and ventricular tachycardias) and early 
deaths after an AMI with respect to control ani-
mals or animals injected with an inert analogue of 
creatine. The present results show that creatine, 
while having no effects on cardiac electrical and 
mechanical activities, significantly increased the 
ventricular fibrillation threshold after an AMI in 
isolated rat hearts. A decreased activation of the 
TRPC3/C7 channels during the early phase of 
AMI can underlie the antiarrhythmic action of 
creatine. This can be explained as follows: We 
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have shown that ATP, released during the early 
phase of an AMI, activates, via a complex signa-
ling cascade, the cationic (nonspecific) channel 
TRPC3/C7.6 In the presence of excess creatine, 
ecto-nucleoside diphosphate kinases, NDPK, 
could significantly decrease the (released) inters-
titial ATP concentration by transferring phosphate 
groups between ATP and creatine to form crea-
tine phosphate and ADP which is inactive on the 
TRPC3/C7 channel. Therefore, the depolarizing 
arrhythmogenic current through TRPC3/C7 chan-
nel will be significantly diminished and as a con-
sequence, fewer arrhythmias occur.  
To our knowledge, antiarrhyhthmic actions of 
creatine have been only reported by our laborato-
ries. However, several studies suggest a cardio-
protective action for creatine phosphate (CrP) 
since, through NDPK it can serve as a buffer for 
ATP in energy-depleted hearts.13-15 Another study 
proposed that CrP could have an antiarrhythmic 
action due to its capacity to reduce degradation 
of membrane phospholipids thus diminishing 
lisophosphoglyceride production (LPG).16 It has 
been shown that LPG accumulates in the ischem-
ic zone causing electrical instability and arrhyth-
mias.17 
 
CONCLUSIONS 
 
We may conclude that creatine, by increasing 
the ventricular fibrillation threshold during an 
acute myocardial infarction, could have an anti-
arrhythmic action. Although more preclinical stu-
dies are still necessary, our results suggest that 
creatine could be used as a therapeutic agent to 
prevent arrhythmias during ischemia or reperfu-
sion. 
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